medigraphic.com
ISSN 0016-3813 (Print)

2014, Number S2

<< Back Next >>

Gac Med Mex 2014; 150 (S2)

Cutaneous Melanoma (CM): Current Diagnosis and Treatment

Gallegos HJF, Nieweg OE

Language: Spanish
References: 42
Page: 175-182
PDF size: 224.25 Kb.


ABSTRACT

Cutaneous melanoma (CM) is the third most common cancer of the skin, but it is the neoplasia with the greatest impact on mortality. Its etiology is multifactorial and it has been reported that its prevalence has increased in the last two decades. In Mexico, CM ranks seventh in frequency among all malignancies and 80% of cases are in locally advanced stages. The prognosis depends on the stage. The prognostic factors with greatest impact in survival are nodal status, tumor thickness or Breslow depth, ulceration, and in thin melanomas (‹ 1 mm thickness, without ulceration and Clarck level III), the mitotic index. The diagnostic approach is of great importance to achieve adequate treatment. Adherence to global guidelines of treatment allows us to obtain the best rates of locoregional control, which is the first target to be achieved in patients with CM. The goal of this manuscript is to provide a synthesis of the most important aspects in the diagnosis and treatment of CM, based on current evidence obtained in the literature.


REFERENCES

  1. Kulesa PM, Kasemeier-Kulesa JC, Teddy JM, et al. Reprograming metastatic melanoma cells to assume a neural cresta cell-like phenotype in an embruonic microenviroment. Proc Natl Acad Sci USA. 2006;103(10):3752-7.

  2. Puig S, Puig-Butille JA, Badenas C, Cuellar F, Malvehy. Novedades genéticas en melanoma. Piel. 2006;21:272-4.

  3. De la Fuente-García A, Ocampo-Candiani J. [Cutaneous melanoma]. Gac Med Mex. 2010;146(2):126-35.

  4. Gallegos-Hernández JF. Melanoma cutáneo. La importancia de la fotoprotección y del diagnóstico oportuno. Cir Cir. 2008;76:363-6.

  5. Naeyaert JM, Brochez L. Clinical practice. Dysplastic nevi. N Engl J Med. 2003;349(23):2233-40.

  6. Ivry GB, Ogle CA, Shim EK. Role of sun exposure in melanoma. Dermatol Surg. 2006;32(4):481-92.

  7. Fernández-Flores A. Prognostic factors for melanoma progresión and metastasis: from hematoxylin-eosin to genetics. Rom J Morphol Embryol. 2012;53(3):449-59.

  8. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351(10):998-1012.

  9. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36): 6199-206.

  10. Edge SB, Carducci M, Byrd DR, editores. AJCC Cancer Staging Manual. 7.a ed. Nueva York: Springer-Verlag New York, LLC; 2009.

  11. Sober AJ, Chuang TY, Duvic M, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol. 2001;45(4):579-86.

  12. Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004;11(4):426-33.

  13. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97(6):1488-98.

  14. Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2007;109(1):100-8.

  15. RossMI, Gershenwald JE. Evidence-based treatment of early-stage melanoma. J Surg Oncol. 2011;104:341-53.

  16. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25(9):1129-34.

  17. Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO melanoma program experience. Ann Surg Oncol. 2000;7(6):469-74.

  18. Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012;30(23): 2912-8.

  19. Garbe C, Eigentler TK, Bauer J, et al. Histopathological diagnostics of maligant melanoma in accordance with the recent AJCC classification 2009: review of the literature and recommendations of general practice. J Dtsch Dermatol Ges. 2011;9(9):690-9.

  20. Buzaid AC, Sandler AB, Mani S, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol. 1993;11(4):638-43.

  21. Pandalai PK, Dominguez FJ, Michaelson J, Tanabe KK. Clinical value of radiographic staging in patients diagnosed with AJCC stage III melanoma. Ann Surg Oncol. 2011;18(2):506-13.

  22. Buzaid AC, Tinoco L, Ross MI. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol. 1995;13(8):2104-8.

  23. Clark PB1, Soo V, Kraas J, Shen P, Levine EA. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg. 2006;141(3):284-8.

  24. Maubec E, Lumbroso J, Masson F, et al. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. Melanoma Res. 2007;17(3): 147-54.

  25. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg. 1991;126(4): 438-41.

  26. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 1993;218(3): 262-7.

  27. Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer. 2000;89(7): 1495-501.

  28. Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer. 2003;97(8):1941-6.

  29. Thomas JM, Newton-Bishop J, A’Hern R, et al. Excision margins in highrisk malignant melanoma. N Engl J Med. 2004;350(8):757-66.

  30. Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg. 2003;46(6):419-26.

  31. Buettiker UV, Yawalkar NY, Braathen LR, Hunger RE. Imiquimod treatment of lentigo maligna: an open-label studyin 32 patients. Arch Dermatol. 2008;144(7):943-5.

  32. Gallegos-Hernández JF, Martínez-Gómez H, Flores-Díaz R. La disección radical de cuello en cáncer de vías aero-digestivas superiores. Indicaciones, extensión y radicalidad. Cir Cir. 2002;70:369-76.

  33. Pasquiali S, Spillane AJ, de Wilt JH, et al. Surgeons’ opinions on lymhadenectomy in melanoma patients with positive sentinel nodes: A worldwide web-based suvey. Ann Surg Oncol. 2012;19(13):4322-9.

  34. Chakera AH, Hesse B, Burak Z, et al. EANM-EORTC general recomendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging. 2009;36(10):1713-42.

  35. Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the multicenter selective lymphadenectomy trial (I). Ann Surg Oncol. 2010;17(12):3324-9.

  36. Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G; ESMO Guidelines Working Group. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment adn follow-up. Ann Oncol. 2012;23 Suppl 7:vii86-91.

  37. Ulrich J, van Akkoi AJ, Eggermont AM, Voit C. New developments in melanoma: utility of ultrasound (inicial staging, follow-up and pre-SLNB) Expert Rev Anticancer Ther. 2011;11(11):1693-701.

  38. Pilko G, Besic N, Sgajnar J, Hocevar M. Melanoma patients with ultrasonically negative regional lymph node basins have a lower tumour burden in regional lymph nodes. ESSO meeting 2010. p. 483. Bordeaux. [Internet] Disponible en: www.essoweb.org/eursso/e-learning/posters-congress-2010.

  39. Gallegos-Hernández JF. Melanoma; estadificación. Cáncer & Piel. 2012;9:3-12.

  40. Agrawal S, Kane JM 3rd, Guadagnolo BA, Kraybill WG, Ballo MT. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer. 2009;115(24):5836-44.

  41. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-26.

  42. Chapman PB, Hauschild A, Robert C, et al. Improved survival with Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16.




2020     |     www.medigraphic.com